Your heart runs on a lifetime, not a decade

Atherosclerosis is driven by ApoB — the number of atherogenic particles in your blood — accumulated over time. The damage is the area under the curve: particle concentration multiplied by years of exposure [Ference BA, 2017].

Lifetime exposure (the number that matters)

Total exposure to age 80: 4200 mg·years. Stays under the illustrative threshold across this range.

Sources

Lowering ApoB earlier shrinks the area dramatically — that’s why a 10-year risk score, which under-weights younger people, misses the point for prevention.

Where does your ApoB sit?

ApoB is a better measure of risk than LDL-C alone [Sniderman AD, 2019]. Prevention-optimal targets are lower than population “normal.”

Tier: High

Sources

Lp(a): the genetic multiplier

Risk: Borderline / grey zone

Lp(a) is largely genetic, measured ~once in a lifetime, not meaningfully lowered by statins or lifestyle, and adds to ApoB-driven risk.

Sources

Blood pressure

High blood pressure compounds ApoB-driven risk by accelerating arterial damage. The 2017 ACC/AHA guideline lowered the thresholds — “normal” is now under 120/80 [Whelton PK, 2018].

Category: Stage 1 hypertension

Sources

Statins: which, and when

Intensity LDL-C lowering Typical regimens When used
high ≥50% Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg Clinical ASCVD, LDL-C ≥190 mg/dL, or high estimated risk; goal of maximal lowering.
moderate 30–49% Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg, Pravastatin 40–80 mg Intermediate risk, or when high-intensity is not tolerated.
low <30% Pravastatin 10–20 mg, Simvastatin 10 mg When higher intensities are not tolerated.

Sources

Educational only. See the disclaimer below before acting on any of this.